Lunch & Learn PSCC X FHU Care – How to decouple efficacy and immune side effects in immunotherapies for cancer?

The PSCC invites you to a new lunch and learn on the theme:

How to decouple efficacy and immune side effects in immunotherapies for cancer?

📍 Available both onsite at PSCC and online

With: Maxime Ilzkovitz Praticien Hospitalier Universitaire, spécialiste en médecine interne Service de médecine interne, Institut Jules Bordet

And François-Xavier Danlos, Assistant Professor - Drug Development Department, Gustave Roussy

Maxime Ilzkovitz graduated in medicine from the Université libre de Bruxelles (ULB) and is an internal medicine specialist who has been working for the past three years at the Institut Jules Bordet in Brussels, at the heart of immuno-oncology care. He developed a strong interest in autoimmune diseases before focusing on the spectrum of immune-related adverse events associated with immune checkpoint inhibitors. 

At Jules Bordet, his clinical and academic activity is dedicated to building and structuring a Competence Centre for Immunotoxicity Management, in close collaboration with thoracic oncologists for patients treated with immunotherapy. He is an active member of BiTOX, the belgian multidisciplinary immunotoxicity board. 

He is now starting a PhD project on immune-related adverse events, with a specific focus on cancer patients with pre-existing dysimmune conditions.

Lunch & Learn – A new format introduced by PSCC Concise, interactive, and hosted onsite at PSCC, this lunch session is designed to foster direct exchanges with an academic expert. The goal: to enable members of the ecosystem to gain first-hand insights on a scientific or strategic topic related to innovation in oncology, in a small-group setting.

👉 Register now!